These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23749668)

  • 1. Chronic hepatitis B: a treatment update.
    Wong VW; Chan HL
    Semin Liver Dis; 2013 May; 33(2):122-9. PubMed ID: 23749668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
    Chien RN
    J Gastroenterol Hepatol; 2010 May; 25(5):852-7. PubMed ID: 20546437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.
    Yap DY; Tang CS; Yung S; Choy BY; Yuen MF; Chan TM
    Transplantation; 2010 Aug; 90(3):325-30. PubMed ID: 20562676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
    Papatheodoridis GV
    Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutic targets and drugs for the treatment of chronic hepatitis B.
    Fletcher SP; Delaney WE
    Semin Liver Dis; 2013 May; 33(2):130-7. PubMed ID: 23749669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.
    Dusheiko G
    Liver Int; 2013 Feb; 33 Suppl 1():137-50. PubMed ID: 23286858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue.
    Ma H; Jia J
    Liver Int; 2013 Feb; 33 Suppl 1():133-6. PubMed ID: 23286857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
    Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
    Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
    Zhang Y; Lian JQ; Li Y; Wang JP; Huang CX; Bai XF; Wang JP
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):814-9. PubMed ID: 23406845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B.
    Fung J; Lai CL; Yuen MF
    Expert Rev Anti Infect Ther; 2010 Jun; 8(6):717-26. PubMed ID: 20521898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides.
    Nguyen MH; Keeffe EB
    J Viral Hepat; 2009 Mar; 16(3):149-55. PubMed ID: 19236641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.
    Güzelbulut F; Ovünç AO; Oetinkaya ZA; Senates E; Gökden Y; Saltürk AG; Sezikli M; Ozkara S; Cetinkaya F
    Hepatogastroenterology; 2012; 59(114):477-80. PubMed ID: 21940383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations.
    Yuen MF; Ahn SH; Chen DS; Chen PJ; Dusheiko GM; Hou JL; Maddrey WC; Mizokami M; Seto WK; Zoulim F; Lai CL
    J Clin Gastroenterol; 2016 Apr; 50(4):286-94. PubMed ID: 26840752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.